Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial

Background: We performed a randomized, controlled, assessor-blinded, multicenter, non-inferiority (NI) study to compare the safety and efficacy of a ready-to-drink formulation of sodium picosulfate, magnesium oxide, and citric acid (SPMC oral solution) with a powder formulation (P/MC powder) for ora...

Full description

Bibliographic Details
Main Authors: Lawrence Hookey, Gerald Bertiger, Kenneth Lee Johnson, Julia Ayala, Yodit Seifu, Stuart P Brogadir
Format: Article
Language:English
Published: SAGE Publishing 2019-05-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756284819851510
id doaj-94cdeb04b2014690bf17209485de6779
record_format Article
spelling doaj-94cdeb04b2014690bf17209485de67792020-11-25T02:48:07ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482019-05-011210.1177/1756284819851510Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trialLawrence HookeyGerald BertigerKenneth Lee JohnsonJulia AyalaYodit SeifuStuart P BrogadirBackground: We performed a randomized, controlled, assessor-blinded, multicenter, non-inferiority (NI) study to compare the safety and efficacy of a ready-to-drink formulation of sodium picosulfate, magnesium oxide, and citric acid (SPMC oral solution) with a powder formulation (P/MC powder) for oral solution. Methods: Eligible participants (adults undergoing elective colonoscopy) were randomized 1:1 to split-dose SPMC oral solution or P/MC powder. The primary efficacy endpoint assessed overall colon-cleansing quality with the Aronchick Scale (AS), and the key secondary efficacy endpoint rated quality of right colon cleansing with the Boston Bowel Preparation Scale (BBPS). Assessments were performed by a treatment-blinded endoscopist. Tolerability was assessed using the Mayo Clinic Bowel Prep Tolerability Questionnaire. Safety assessments included adverse events and laboratory evaluations. Results: The study included 901 participants: 448 for SPMC oral solution; 453 for P/MC powder. SPMC oral solution demonstrated non-inferiority to P/MC powder {87.7% (393/448) responders versus 81.5% (369/453) responders [difference (95% confidence interval): 6.3% (1.8, 10.9)]}. The key secondary efficacy objective assessing the right colon was also met. According to the prespecified hierarchical testing, after meeting the primary and key secondary objectives, SPMC oral solution was tested for superiority to P/MC powder for the primary endpoint ( p = 0.0067). SPMC oral solution was well tolerated. Most common adverse events were nausea (3.1% versus 2.9%), headache (2.7% versus 3.1%), hypermagnesemia (2.0% versus 5.1%), and vomiting (1.3% versus 0.7%) for SPMC oral solution and P/MC powder, respectively. Conclusions: Ready-to-drink SPMC oral solution showed superior efficacy of overall colon cleansing compared with P/MC powder, with similar safety and tolerability. [ClinicalTrials.gov identifier: NCT03017235.]https://doi.org/10.1177/1756284819851510
collection DOAJ
language English
format Article
sources DOAJ
author Lawrence Hookey
Gerald Bertiger
Kenneth Lee Johnson
Julia Ayala
Yodit Seifu
Stuart P Brogadir
spellingShingle Lawrence Hookey
Gerald Bertiger
Kenneth Lee Johnson
Julia Ayala
Yodit Seifu
Stuart P Brogadir
Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial
Therapeutic Advances in Gastroenterology
author_facet Lawrence Hookey
Gerald Bertiger
Kenneth Lee Johnson
Julia Ayala
Yodit Seifu
Stuart P Brogadir
author_sort Lawrence Hookey
title Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial
title_short Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial
title_full Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial
title_fullStr Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial
title_full_unstemmed Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial
title_sort efficacy and safety of a ready-to-drink bowel preparation for colonoscopy: a randomized, controlled, non-inferiority trial
publisher SAGE Publishing
series Therapeutic Advances in Gastroenterology
issn 1756-2848
publishDate 2019-05-01
description Background: We performed a randomized, controlled, assessor-blinded, multicenter, non-inferiority (NI) study to compare the safety and efficacy of a ready-to-drink formulation of sodium picosulfate, magnesium oxide, and citric acid (SPMC oral solution) with a powder formulation (P/MC powder) for oral solution. Methods: Eligible participants (adults undergoing elective colonoscopy) were randomized 1:1 to split-dose SPMC oral solution or P/MC powder. The primary efficacy endpoint assessed overall colon-cleansing quality with the Aronchick Scale (AS), and the key secondary efficacy endpoint rated quality of right colon cleansing with the Boston Bowel Preparation Scale (BBPS). Assessments were performed by a treatment-blinded endoscopist. Tolerability was assessed using the Mayo Clinic Bowel Prep Tolerability Questionnaire. Safety assessments included adverse events and laboratory evaluations. Results: The study included 901 participants: 448 for SPMC oral solution; 453 for P/MC powder. SPMC oral solution demonstrated non-inferiority to P/MC powder {87.7% (393/448) responders versus 81.5% (369/453) responders [difference (95% confidence interval): 6.3% (1.8, 10.9)]}. The key secondary efficacy objective assessing the right colon was also met. According to the prespecified hierarchical testing, after meeting the primary and key secondary objectives, SPMC oral solution was tested for superiority to P/MC powder for the primary endpoint ( p = 0.0067). SPMC oral solution was well tolerated. Most common adverse events were nausea (3.1% versus 2.9%), headache (2.7% versus 3.1%), hypermagnesemia (2.0% versus 5.1%), and vomiting (1.3% versus 0.7%) for SPMC oral solution and P/MC powder, respectively. Conclusions: Ready-to-drink SPMC oral solution showed superior efficacy of overall colon cleansing compared with P/MC powder, with similar safety and tolerability. [ClinicalTrials.gov identifier: NCT03017235.]
url https://doi.org/10.1177/1756284819851510
work_keys_str_mv AT lawrencehookey efficacyandsafetyofareadytodrinkbowelpreparationforcolonoscopyarandomizedcontrollednoninferioritytrial
AT geraldbertiger efficacyandsafetyofareadytodrinkbowelpreparationforcolonoscopyarandomizedcontrollednoninferioritytrial
AT kennethleejohnson efficacyandsafetyofareadytodrinkbowelpreparationforcolonoscopyarandomizedcontrollednoninferioritytrial
AT juliaayala efficacyandsafetyofareadytodrinkbowelpreparationforcolonoscopyarandomizedcontrollednoninferioritytrial
AT yoditseifu efficacyandsafetyofareadytodrinkbowelpreparationforcolonoscopyarandomizedcontrollednoninferioritytrial
AT stuartpbrogadir efficacyandsafetyofareadytodrinkbowelpreparationforcolonoscopyarandomizedcontrollednoninferioritytrial
_version_ 1724749920195313664